Oncology

Redefining the treatment paradigm to eliminate cancer as a cause of death

Our approach

Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease. At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.

Our focus on unmet needs

  • Immuno-oncology

    Using the body's immune system to help fight cancer


    Watch video
  • Tumour drivers and resistance

    Developing therapies that target specific mutations to attack cancer cells


    Watch video
  • DNA damage response

    Targeting the DNA repair process to block tumour cells' ability to reproduce


    Watch video
  • Antibody-drug conjugates

    Arming antibodies with cancer-killing agents for specific tumour targeting


    Watch video

What we're working on

As part of our commitment to oncology, the following section provides further detail about key areas of focus.

PatientView Survey on use of scientific information

Last year we commissioned a survey to better understand how the patient and caregiver community view the landscape of science communications. Reaching 124 patient and caregiver group representatives, we uncovered the increasing need for accessible scientific information for individuals with cancer and their families.

Our pipeline

Our robust pipeline includes investigational therapies in varied stages of clinical development, from recently approved products to earlier-stage molecules in clinical trials. We aspire to transform the lives of cancer patients, working to eliminate cancer as a cause of death in the future.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Oncology (as at 27 April 2017)

Phase 1

Phase 1

  • AZD0156 solid tumours
  • AZD2811 solid tumours
  • AZD4635 solid tumours
  • AZD6738 solid tumours
  • AZD8186 solid tumours
  • AZD9150 haematological malignancies
  • AZD9496 ER+ breast cancer
  • Lynparza + AZD1775 solid tumours
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI3726 prostate cancer
  • MEDI4276 solid tumours
  • MEDI5083 solid tumours
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • durvalumab + AZD1775 solid tumours
  • durvalumab + Iressa NSCLC
  • durvalumab + MEDI0562 solid tumours
  • durvalumab + MEDI9447 solid tumours
  • durvalumab + dabrafenib + trametinib melanoma
  • durvalumab + monalizumab solid tumours
  • durvalumab + selumetinib solid tumours
  • durvalumab + tremelimumab solid tumours
  • durvalumab or durvalumab + (tremelimumab or AZD9150) diffuse large B-cell lymphoma
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • AZD1775 solid tumours
  • AZD1775 + chemotherapy ovarian cancer
  • AZD4547 solid tumours
  • AZD5363 breast cancer
  • Lynparza + AZD6738 gastric cancer
  • Lynparza + cediranib CONCERTO recurrent platinum resistant ovarian cancer
  • MEDI-573 metastatic breast cancer
  • Tagrisso BLOOM CNS metastases in advanced EGFRm NSCLC
  • Tagrisso (AZD9291) + (durvalumab or selumetinib or savolitinib) TATTON advanced EGFRm NSCLC
  • durvalumab solid tumours
  • durvalumab + AZD5069 durvalumab + AZD9150 HNSCC
  • durvalumab + MEDI0680 solid tumours
  • durvalumab + tremelimumab hepatocellular carcinoma (liver cancer)
  • durvalumab + tremelimumab gastric cancer
  • savolitinib/ volitinib papillary renal cell carcinoma
  • vistusertib solid tumours

Phase 3

Phase 3

  • acalabrutinib B-cell malignancy
  • acalabrutinib 1st line CLL
  • acalabrutinib r/r CLL, high risk
  • durvalumab ≥2nd-line advanced bladder cancer
  • durvalumab PACIFIC stage III NSCLC
  • durvalumab PEARL 1st-line NSCLC
  • durvalumab + tremelimumab ARCTIC 3rd-line NSCLC
  • durvalumab + tremelimumab CASPIAN 1st-line SCLC
  • durvalumab + tremelimumab DANUBE 1st-line bladder
  • durvalumab + tremelimumab EAGLE 2nd-line SCCHN
  • durvalumab + tremelimumab KESTREL 1st-line SCCHN
  • durvalumab + tremelimumab MYSTIC 1st-line NSCLC
  • durvalumab + tremelimumab NEPTUNE 1st-line NSCLC
  • moxetumomab pasudotox PLAIT hairy cell leukaemia
  • selumetinib ASTRA differentiated thyroid cancer

LCM Projects

LCM Projects

  • Faslodex FALCON 1st-line hormone receptor +ve advanced breast cancer
  • Lynparza PROfound prostate cancer
  • Lynparza SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Tagrisso (AZD9291) ADAURA adjuvant EGFRm NSCLC
  • Tagrisso (AZD9291) FLAURA 1st-line advanced EGFRm NSCLC

Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Arimidex anastrozole
  • Casodex, Cosudex bicalutamide
  • Faslodex fulvestrant
  • Iressa gefitinib
  • Lynparza olaparib
  • Nolvadex, Istubal, Valodex tamoxifen citrate
  • Tagrisso osimertinib
  • Zoladex goserelin acetate implant

Partnering to address unmet needs

To eradicate cancer as a cause of death, we understand that we cannot work alone. Improving patient outcomes requires a collaborative approach to research and development.

Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Targeting the DNA damage response in cancer

PUBLISHED
14 October 2015

TITLE
Targeting the DNA damage response in cancer

AstraZeneca/MedImmune AUTHOR
O'Connor MJ

Patient-centric trials for therapeutic development in precision oncology

PUBLISHED
14 October 2015

TITLE
Patient-centric trials for therapeutic development in precision oncology

AstraZeneca/MedImmune AUTHOR
Hollingsworth S.J., Andrew V. Biankin, Steven Piantadosi & Simon J. Hollingsworth

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

PUBLISHED
24 September 2015

TITLE
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

AstraZeneca/MedImmune AUTHOR
Paul D. Smith, Christopher J. Caunt, Matthew J. Sale, Paul D. Smith & Simon J. Cook

Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase

PUBLISHED
23 July 2015

TITLE
Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase

AstraZeneca/MedImmune AUTHOR
Klein T, Vajpai N, Phillips J, Tobias Klein, Navratna Vajpai, Jonathan J. Phillips, Gareth Davies, Geoffrey A. Holdgate, Chris Phillips, Julie A. Tucker, Richard A. Norman, Andrew D. Scott, Daniel R. Higazi, David Lowe, Gary S. Thompson & Alexander L. Breeze

c-kit+ cells adopt vascular endothelial but not epithelial cell fates during lung maintenance and repair

PUBLISHED
13 July 2015

TITLE
c-kit+ cells adopt vascular endothelial but not epithelial cell fates during lung maintenance and repair

AstraZeneca/MedImmune AUTHOR
Wang QD, Qiaozhen Liu, Xiuzhen Huang, Hui Zhang, Xueying Tian, Lingjuan He, Rui Yang, Yan Yan, Qing-Dong Wang, Astrid Gillich & Bin Zhou

An analysis of the attrition of drug candidates from four major pharmaceutical companies

PUBLISHED
19 June 2015

TITLE
An analysis of the attrition of drug candidates from four major pharmaceutical companies

AstraZeneca/MedImmune AUTHOR
Mike Waring (Oncology iMed), Michael J. Waring, John Arrowsmith, Andrew R. Leach, Paul D. Leeson, Sam Mandrell, Robert M. Owen, Garry Pairaudeau, William D. Pennie, Stephen D. Pickett, Jibo Wang, Owen Wallace & Alex Weir

MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis

PUBLISHED
12 May 2015

TITLE
MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis

AstraZeneca/MedImmune AUTHOR
Zheng Liu, Wei Zhu, Yue Wang, Wen Pan, Shu Zhu, Dai Dai, Zheng Liu, Dan Li, Bin Li, Nicola Gagliani, Yunjiang Zheng, Yuanjia Tang, Matthew T. Weirauch, Xiaoting Chen, Wei Zhu, Yue Wang, Bo Chen, Youcun Qian, Yingxuan Chen, Jingyuan Fang, Ronald Herbst, Laura Richman, Bahija Jallal, John B. Harley, Richard A. Flavell, Yihong Yao & Nan Shen

Low-frequency coding variants at 6p21.33 and 20q11.21 are associated with lung cancer risk in Chinese populations

PUBLISHED
May 2015

TITLE
Low-frequency coding variants at 6p21.33 and 20q11.21 are associated with lung cancer risk in Chinese populations

AstraZeneca/MedImmune AUTHOR
Brandon Higgs (Oncology, MedImmune)

Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress

PUBLISHED
January 2015

TITLE
Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress

Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome

PUBLISHED
14 January 2015

TITLE
Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome

AstraZeneca/MedImmune AUTHOR
Kohlmann A, Vikas Madan, Deepika Kanojia, Jia Li, Ryoko Okamoto, Aiko Sato-Otsubo, Alexander Kohlmann, Masashi Sanada, Vera Grossmann, Janani Sundaresan, Yuichi Shiraishi, Satoru Miyano, Felicitas Thol, Arnold Ganser, Henry Yang, Torsten Haferlach, Seishi Ogawa & H. Phillip Koeffler

Resources



Veeva ID: Z4-3401
Date of next review: March 2018